Your browser does not support flash 8 or later which is needed to view this animation. Please visit www.macromedia.com/go/getflashplayer to download the flash player.

Nexavar — Demonstrated a Statistically Significant Advantage in Overall Survival vs Placebo in HCC¹

Nexavar — Demonstrated a Statistically Significant Advantage in Overall Survival vs Placebo in HCC

CI=confidence interval; HR=hazard ratio.
^aStatistically significant because the P value was below the prespecified O'Brien-Fleming stopping boundary of .0077.

Data from SHARP, a double-blind, randomised, placebo-controlled, multicentre, phase III trial that compared Nexavar 400 mg bid (n=299) to placebo (n=303) in patients with HCC. Additional informations about the pivotal study: The SHARP Trial.

• 44% survival at 1 year vs 33% with placebo¹
• Survival advantage consistent across the majority of subsets analysed⁹

Nexavar — doubled the median time to tumour progression (TTP) vs placebo (P<.001)¹

Nexavar — doubled the median time to tumour progression (TTP) vs placebo (P

Data from SHARP, a double-blind, randomised, placebo-controlled, multicentre, phase III trial that compared Nexavar 400 mg bid (n=299) to placebo (n=303) in patients with HCC. Additional informations about the pivotal study: The SHARP Trial.

Next: Nexavar Safety in HCC

 

Term

Explanation for term.